Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .Uncertainty is everywhere. And while the stock market isn't even in correction territory, investors are clearly nervous, as we'reIf all of my articles over the past few weeks had to be summarized by one word, I think it would be "uncertainty."Analyst’s Disclosure: I/we have a be ...

Investor enthusiasm hit a fever pitch following the 2024 election, but took a punch to the gut recently. Market indexes have been falling as investors are beginning to assume President Trump will make good on repeated promises to raise the cost of goods entering the U.S. from the country's largest trading partners through tariffs.The biggest trade war losers to date have been the richly valued tech stocks at the top of the S&P 500 (^GSPC 1.08%) index. All the "Magnificent Seven" stocks finished March 18 dow ...

Pfizer (PFE) closed the most recent trading day at $26.21, moving -0.38% from the previous trading session. This move lagged the S&P 500's daily gain of 1.08%. Meanwhile, the Dow gained 0.92%, and the Nasdaq, a tech-heavy index, added 1.41%.The the stock of drugmaker has risen by 2.93% in the past month, leading the Medical sector's gain of 0.21% and the S&P 500's loss of 8.26%.The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. On that day, Pfiz ...

Since my last coverage , Pfizer (NYSE: PFE ) has remained relatively stable, while the S&P 500 declined by 2.25%, a reflection of its defensive attractiveness in a risk-off environment. Its bull case is centered in its core pharma growth, expanding beyond pandemicYiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certified Accou ...

Pfizer’s (PFE) stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple of years due to declining sales of its COVID products with the end of the pandemic.After witnessing possibly its worst slowdown in 2023/2024, the company seems to be gradually making a comeback and entering a transition phase. Its non-COVID drugs and contributions from new and newly acquired products have started t ...

Group 1 - The article is the first in a series of comparative analyses between two pharmaceutical companies, with plans to publish one article each week over the next four weeks [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical companies [2] - The company aims to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2] - Allka Research seeks to share its insights through Seeking Alpha, contributing analyses and perspectives to empower financial decision-making [2]

When it comes to dividend investing, some are adamant that dividends don't matter but are just the removal of value from the company's share price. Instead, they think that selling shares to create your own synthetic dividendContributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do thei ...

If you want to generate significant long-term gains in the stock market, one place to start looking for investments is among the companies that Wall Street isn't all that thrilled with today. In the short term, these may not be good performers, and they may not have looked like great buys in recent months or years. But there can be winners to be found among cheaply valued stocks. The trick is to pick out the diamonds in the rough that have a lot of upside potential in the long run.Verizon Communications (VZ ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. However, even in a bull market, like the one we're currently experiencing, it's possible to find attractive companies to invest in at attractive prices.For that, look no further than the pharmaceutical giant Pfizer (PFE -1.43%). The drugmaker has significantly lagged the market in the past three years. But at its current levels, Pfizer might be a steal for long-term investors. ...

In my last article about Pfizer Inc. (NYSE: PFE ), I argued that the low price and high dividend might offset the expanding risks. In the meantime, an investment would have returned about 5% and although this does not seem likeMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization ...